From NFL training facilities to Olympic villages, hyperbaric oxygen therapy chambers have become an increasingly familiar sight in elite sports. Athletes seeking any competitive edge—faster recovery between games, reduced soreness after brutal workouts, quicker healing from injuries—have embraced HBOT as a cutting-edge modality. But does the science actually support the hype? A comprehensive narrative review published in the Undersea and Hyperbaric Medicine Journal in 2025 offers a sobering assessment: the evidence is real but limited, and the marketing often runs ahead of the data.
The Promise: How HBOT Could Theoretically Help Athletes
The physiological rationale for hyperbaric oxygen therapy in sports medicine is grounded in well-established mechanisms. During HBOT, patients breathe 100% oxygen in a pressurized chamber—typically at 2.0 to 2.5 atmospheres absolute (ATA), roughly equivalent to diving 33 to 50 feet underwater. This pressure gradient dramatically increases the amount of dissolved oxygen in blood plasma, allowing oxygen to reach tissues even when hemoglobin is already saturated.
For athletes, this hyperoxygenation could theoretically accelerate several recovery processes:
Muscle healing and tissue repair. Animal studies consistently demonstrate that HBOT promotes angiogenesis (new blood vessel formation), collagen synthesis, and extracellular matrix remodeling—processes essential for healing soft-tissue injuries. In rodent models of muscle contusion and strain, HBO₂-treated animals show faster regeneration of muscle fibers and reduced fibrosis compared to controls.
Inflammation modulation. Intense exercise triggers acute inflammatory cascades that, while necessary for adaptation, can impede short-term recovery. HBOT appears to modulate pro-inflammatory cytokines and reduce oxidative stress in damaged tissues—potentially shortening the window between peak exertion and return to performance.
Edema reduction. The pressure differential in hyperbaric chambers may help reduce swelling in injured tissues, improving range of motion and functional capacity during rehabilitation.
Neurobehavioral recovery. For athletes recovering from concussion or traumatic brain injury, HBOT’s potential to reduce neuroinflammation and promote neuroplasticity has attracted particular interest, given the devastating career impact of persistent post-concussion symptoms.
What the 2025 UHMS Review Actually Found
Dr. Kelly Johnson-Arbor’s narrative review, published in the third quarter of 2025, systematically examined human and animal literature on HBOT applications relevant to athletes. The findings paint a nuanced picture—more encouraging than skeptics might expect, but far from the unequivocal endorsement some clinics advertise.
Soft-Tissue Musculoskeletal Injuries: The Strongest Signal
The review identifies soft-tissue injuries as the application with the most supportive evidence. While acknowledging that human studies remain “inconclusive” overall, Dr. Johnson-Arbor notes that “some data suggest that short courses of HBO₂ may result in reduced pain and faster return to play after soft tissue musculoskeletal injury.”
Several small randomized trials support this conclusion. In studies of athletes with acute muscle strains, contusions, and ligament sprains, those receiving HBOT reported less pain and returned to competition sooner than control groups receiving standard rehabilitation alone. The effect sizes were modest but clinically meaningful for elite athletes where days matter.
Concussion and Traumatic Brain Injury: Limited but Intriguing
For the subset of athletes dealing with post-concussion syndrome, the review finds “limited data suggest that HBO₂ may improve neurobehavioral symptoms.” This conclusion aligns with broader research on HBOT for TBI, where some studies show cognitive and symptom improvements while others find no benefit over sham treatment.
Importantly, the review emphasizes that “studies involving the use of hyperbaric oxygen therapy to treat concussions in athletes are limited”—a critical caveat given how frequently HBOT is marketed to this vulnerable population.
Post-Exercise Recovery and Performance Enhancement: The Weakest Link
Perhaps most relevant to the average athlete’s interest in HBOT is whether it enhances recovery between training sessions or improves performance. Here, the review is unequivocal: “Overall, there is limited evidence to support the use of HBO₂ to enhance recovery in athletes with musculoskeletal and mild traumatic brain injury.”
The 2025 meta-analysis by Luo et al. in the Archives of Physical Medicine & Rehabilitation reinforces this conclusion. Analyzing ten randomized controlled trials comprising 299 subjects, the authors found that while HBOT showed some effects on exercise-induced muscle damage markers, the clinical significance for routine athletic recovery remained uncertain. The studies were heterogeneous in design, HBOT protocols varied widely, and outcome measures lacked standardization—limiting the strength of any recommendation.
The Safety and Regulatory Landscape
The FDA’s August 2025 letter to healthcare providers casts a long shadow over the athletic HBOT market. The agency reminded clinicians that hyperbaric oxygen therapy devices are cleared for specific medical indications—not for general wellness, athletic performance enhancement, or routine recovery. Using these devices off-label for athletic applications, while not prohibited, carries regulatory and safety implications.
More concerning is the proliferation of “mild” or “soft” hyperbaric chambers—devices operating at lower pressures (typically 1.3 ATA) that have flooded the consumer market. These chambers, often marketed directly to athletes and wellness enthusiasts, occupy a regulatory gray area. As Dr. Johnson-Arbor notes, “The treatment vessels used to deliver mild HBO₂ are typically intended for treating altitude sickness only. They are associated with safety and regulatory concerns when used for other purposes, including athletic recovery.”
The FDA’s 2025 warning specifically highlighted fire risks and the importance of following manufacturer instructions—concerns amplified in non-medical settings where supervision may be minimal. Several high-profile incidents, including fatalities in hyperbaric chamber fires at wellness centers, underscore that these devices are not benign consumer appliances.
The Marketing vs. Reality Gap
Walk into any high-end sports performance center or browse athletic recovery clinics in major cities, and you’ll likely find hyperbaric oxygen therapy prominently featured. The pitch is seductive: professional athletes use it, the science is “proven,” and the only barrier to faster recovery is your willingness to climb into the chamber.
This marketing narrative exploits a fundamental asymmetry in how evidence propagates. Animal studies showing muscle healing get translated into confident claims about human athletic performance. Small pilot studies with mixed results become “clinical proof” in promotional materials. The cautious language of scientific papers—“may,” “suggests,” “limited evidence”—morphs into definitive assertions of efficacy.
The 2025 UHMS review offers a necessary corrective. Yes, there is biological plausibility. Yes, some studies show benefits for specific injury types. But the evidence base for HBOT as a routine athletic recovery tool remains thin, and the claims made by many commercial providers outpace what peer-reviewed research supports.
What Athletes Should Actually Consider
For athletes contemplating hyperbaric oxygen therapy, the evidence suggests a targeted rather than scattershot approach:
Acute soft-tissue injuries represent the most defensible use case. If you’re dealing with a significant muscle strain, ligament sprain, or contusion that threatens to sideline you, a short course of HBOT—administered in a properly accredited medical facility—may modestly accelerate your return to play. The effect isn’t dramatic, but for professional athletes where days matter, it may be worthwhile.
Post-concussion syndrome is more complex. While some athletes report symptom improvement, the evidence is mixed and HBOT should be considered only as part of a comprehensive concussion management protocol, not a standalone cure.
Routine recovery between workouts has the weakest support. The meta-analytic evidence simply doesn’t support investing significant time and money in HBOT for standard training recovery when sleep, nutrition, and active rest protocols offer proven benefits at far lower cost.
Facility choice matters enormously. The UHMS and FDA emphasize that HBOT should be administered in accredited facilities with appropriate medical oversight. The “soft chamber” at your local wellness center may be convenient, but it may also lack the safety protocols, emergency equipment, and trained staff that hospital-based hyperbaric units maintain.
The Bottom Line
Hyperbaric oxygen therapy occupies a familiar space in sports medicine: a treatment with genuine physiological mechanisms, some supportive evidence for specific applications, and a vast gap between what science supports and what marketing promises. The 2025 UHMS narrative review doesn’t dismiss HBOT for athletes—it identifies real signals in soft-tissue injury recovery—but it places those signals in proper context.
For athletes, the takeaway is pragmatic. HBOT is not a performance-enhancing silver bullet. It may offer modest benefits for specific injury types when administered properly. The decision to pursue treatment should weigh the quality of local facilities, the specific nature of the injury, the cost (rarely covered by insurance for athletic indications), and realistic expectations about outcomes.
As research continues—particularly the large-scale trials examining HBOT for traumatic brain injury that may indirectly inform concussion management—the evidence base will evolve. Until then, athletes should approach hyperbaric oxygen therapy with the same skepticism they should bring to any expensive recovery modality: demand evidence, verify credentials, and beware of anyone promising miracles in a pressurized tube.